

MicroPhage MRSA/MSSA Screening Test

Rates of *S. aureus* infections have increased dramatically over the last 20 years in North America and much of Europe, and instances of methicillin-resistant *S. aureus* have also increased. Facing legislative and insurer pressure to reduce hospital acquired infections (HAIs), healthcare institutions are looking for ways to affordably screen patients for *S. aureus*.

Receive rapid answers for better infection control

With the MicroPhage MRSA/MSSA Screening Test, clinicians can quickly and affordably identify *S. aureus* and differentiate methicillin-resistant *S. aureus* (MRSA) patients from methicillin-susceptible *S. aureus* (MSSA) colonized patients. Ideal for any institution concerned with screening for all *S. aureus* in their patients, MicroPhage's test delivers comprehensive, rapid results without requiring expensive equipment, specialized personnel, or batching. The MicroPhage MRSA/MSSA Screening Test enables healthcare facilities to create an active surveillance program that can help to significantly reduce HAIs.

- » **Affordably screen patients** – Receive molecular performance at less than half the cost.
- » **Receive appropriate time to results** – Get all of the previous day's results first thing the next morning for infection control and bed management.
- » **Cover multiple body sites** – Capture more colonized patients and better define cleared patients.
- » **Conduct full-coverage testing** – Identify all *S. aureus* carriers, and distinguish MSSA and MRSA colonization for appropriate management.
- » **Easily implement screening programs** – Visually interpret results in unbatched starts without investing in molecular tests or waiting on traditional microbiology.
- » **Reduce hospital-acquired infections (HAIs)** – Enable proactive and effective decolonization, prophylaxis, and/or isolation.



High-value diagnostic, easy-to-use platform

The MicroPhage MRSA/MSSA Screening Test delivers rapid results that enable cost-effective patient screening and infection control. The test itself is simple to perform and does not require expensive equipment, making this critical diagnostic available to all institutions – large and small.

- » Three minutes of hands-on time
- » Unbatched test format
- » Visual interpretation
- » All results available the next morning
- » Pricing that is in line with chromogenic culture media
- » Specificity in the high 90s
- » Sensitivity in the mid 90s



Availability: Late 2010

This test is not cleared by the U.S. FDA nor CE Marked and not yet available for sale.

www.microphage.com
303.652.5200